

March 13, 1969

Dr. Karl M. Aljian
Department of Medical Services
A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia 23220

Dear Dr. Aljian:

I must apologize for not having answered you sooner but I have just returned from a vacation and professional meetings to find your letter.

With regard to your question of ophthalmologic studies on chronic butaperazine patients, I regret that systematic ophthalmologic studies were not done before or after butaperazine therapy.

In reviewing the subjective complaints and symptoms of our patients who have received or are receiving butaperazine, blurring of vision was a complaint of one patient and this improved after reduction of dosage. My associate recalls two other instances of blurring of vision which was transient without change of treatment.

Despite specific inquiry, my associates recall no other ocular symptoms or signs.

At the present time there are four patients receiving butaperazine for periods exceeding one month. If it would be of some merit to have you examine these patients, I am sure we can arrange this.

Thank you for your inquiry.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp